Formulation And Evaluation Of Osmotically Controlled Drug Delivery System Of An Anti-Diabetic Drug
Main Article Content
Abstract
Saxagliptine has a relatively short elimination half-life (2.5 h), thereby requiring twice or thrice daily dosing in patients, which may lead to non-compliance. Extended release formulation of Saxagliptine based on osmotic technology was developed and evaluated. Controlled Porosity osmotic tablets of Saxagliptine were developed using Self Pore forming agent Mannitol. Prepared tablets were evaluated for their Flow property, weight variation, hardness, friability and content uniformity. Tablets were coated with a semi permeable membrane using 6% w/v cellulose acetate Phthalate (CAP) in isopropyl alcohol and Methylene chloride and Polyethylene Glycol-400 as plasticizer. Drug release rate was increased as the increase of Mannitol amount in Core Tablet. Drug release was inversely proportional to weight gain but directly proportional to the Self pore forming agent. The drug release from developed formulations was independent of pH and agitation intensity of release media. The DSC and FTIR studies demonstrated that there was no interaction between polymers and drug. The optimized formulation was stable after one months of accelerated stability studies
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
T W Lee, J R Robinson, In Remington: The science and practice of pharmacy, Gennaro, Ed.; Lippincott Williams and Wilkins: Baltimore.2000;(2):903-929.
R.K. Verma.S.Garg, Current status of drug delivery technologies and future directions, Pharm. Technol.-On Line (http: / /www.pharmaportal.com).2001 ;( 25):1-14.
Vyas S.p, khar R. k. Controlled drug delivery concepts and advances; osmotically regulated systems.(1):477-501
Rajan .K.Verma, Sanjay Garg. Formulation aspects in the development of Osmotically Controlled Oral Drug Delivery systems, J Contr Release.2002 ;( 76):7-27.
Welling P. G. and Dobrinska M. R., Dosing consideration and bioavailability assessment of controlled drug delivery system, Chapter 7, Controlled drug delivery; fundamentals and applications, 2nd edition, Robinson J.R. and Lee V. H. L. (Eds.), Marcel Dekker Inc., New York.1978;(2):254, 373.
Martin A. Phyical Pharmacy, Lippincott Williams and Wilkins.1994; (4):116-117.
Vyas S.p, khar R. k. “controlled drug delivery concepts and advances”;osmotically regulated systems, (1):477-501.
Rajan K. Verma, Sanjay Garg. “Formulation aspects in the development of osmotically controlled oral drug delivery systems”, J Controlled Release.2002;(79):7–27.
Jain N.K. “Advances in Novel and Controlled Delivery”:18-39.
Theeuwes, F., Elementary osmotic pump, J. Pharm.Sci., 1975,1987,1991:(64).
Liberman, H. A., Lachman, L., and Schwartz, J. B., Pharmaceutical Dosage Forms: Tablets, 2nd Edn., Marcel Dekker, New York, 2005;(3):280-282.
Verma, R.K., Krishna, D.M. and Garg, S., Formulation aspects in the development of osmotically controlled oral drug delivery systems, J. Contr. Release.2002;(79):7-27.
Zentner, G.M., Rork, G.S., and Himmelstein K.J., 1990, US Patent No 4968507.
Verma, R.K., Mishra, B. and Garg, S., Osmotically controlled oral drug delivery, Drug Dev. lnd. Pharm.,2000;(26):695-708.
http//www.expresspharmaonline.com/20030828/ research01.html
Gupta roop ,Gupta rakesh,,Rathore Garvendra “ Osmotically controlled drug delivery systems- A review” Int. J. Ph. Sci., Sept-December 2009;(1):271;(2):269-275.
Gaylen ZM, Gerald SR, Kenneth JH. J Contr. Release 1985; (1): 269-282.
Longxiao Liu , Gilson Khang , John M. Rhee , Hai Bang Lee.“Monolithic osmotic tablet system for nifedipine delivery”, J Contr. Release .2000;(67):309–322.
Longxiao Liu, Jeong Ku, Gilson Khang, Bong Lee, John M Rhee, Hai Bang Lee. J Contr. Release.2000; (68):145–156.
Liotta LA, Steeg PS, Stetler-Stevenson WG. Cell 1997 ;( 64):327-336.
Stepkowski SM, Tu Y, Condon TP, Bennett CF. J Immunology.1994; (153):5336-5346.
Liang C Dong, Patrick Wong, Jason Wan, Keru Shafi. Drug Delivery Technology.2002 ;( 1):2.
Stuti G, Ravindra PS, Rohitashva S. Int J Comprehensive Pharm. 2011; (6):1.
Gadwal P, Rudrawal P. Int J Pharm & Life Scie.2010 ;( 6):302-312.
Sharma S, Singh SP, Bhardwaj S, Gaurave K, Gupta GD. Latest Reviews [Internet].Available from: www.pharmainfo.net/reviews/osmotic-controlled-drug-delivery-system 2008;6.
Rastogi SK, Vaya N, Mishra B. East Pharm 1995;(380:79-82.
B Lindstedt, G Ragnarsson, J Hjartstam. Int J Pharm 1989; (56): 261–268.
LA Seminoff, GM Zentner. Cellulosic coating, US patent 5, 1992:126-146.
Tanmoy Ghosh, Amitava Ghosh. Journal of Applied Pharmaceutical Science 2011; 1 (2): 38-49.
GM Zentner, GS Rork, KJ Himmelstein. US patent 4.1990:968,507.
Rajagopal K, Nallaperumal N, Venkatesan S. Lipids in Health and Disease 2011; (10): 51.
Martin A, Bustamante P, Chun AHC.Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences,4th Ed. Philadelphia: Lea and Febiger.1993.
.Babu CA, Rao MP, Ratna V, Controlledporosity osmotic pump tablets- an overview. JPRHC. January2010; 2(1):114-26.
Wong PSL, Edgen DE, Dong LC, Dove Cp,Inventors; ALZA Corporation, Palo Alto, CA, Assignee. Controlled release liquid active agent formulation dosage forms. US patent 6 ,596 ,314. 2003 Jul 22.
Thakor RS, Majumdar FD, Patel JK and Rajaput Review GC. Osmotic drug delivery systems current scenario. 2010;(34):771-775.
Tanmoy G and amitava G. Drug delivery through osmotic systems– an overview. J applied pharm scie.2011;01(02):38-49
A. G. Thombre, G. M. Zentner, K. J. Himmelstein, Mechanism of water transport in controlled porosity osmotic devices, Journal of Membrane Science.1989;(40):279–310.
M.T. amEnde, S.M. Herbig, R.W. Korsmeyer, M.B. Chidlaw, Osmotic drug delivery from asymmetric membrane filmcoated dosage forms, in: D. L. Wise (Ed.), Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, NY.2000:751–785.
S.M. Herbig, J.R. Cardinal, R.W. Korsmeyer, K.L. Smith, Asymmetric-membrane tablet coatings for osmotic drug delivery, J Contr. Release.1995(35):127–136.
A.G. Thombre, J.R. Cardinal, A.R. DeNoto, S.M. Herbig, K.L. Smith, Asymmetric membrane capsules for osmotic drug delivery: I. Development of a manufacturing process, J Contr. Release.1999;(57):55–64.
A. G. Thombre, J. R. Cardinal, A. R. DeNoto, S. M. Herbig, K. L. Smith, Asymmetric membrane capsules for osmotic drug delivery: II. In vitro and in vivo drug release performance, J Contr. Release.199 ;( 57):65–73.
A.G. Thombre, A.R. DeNoto, D.C. Gibbes, Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients, J Contr. Release. 1999 ;( 60):333– 341.
A.G. Thombre, L.E. Appel, M.B. Chidlaw, P.D. Daugherity, F. Dumont, L.A.F. Evans, S.C. Sutton, Swellable core technology for osmotic drug delivery, 29th Annual Meeting of the Controlled Release Society, July 20– 25, Seoul, Korea.
L.E. Appel, R.A. Beyerinck, M.B. Chidlaw, W.J. Curatolo, D.T. Friesen, K.L. Smith, A.G. Thombre, Hydrogeldriven drug dosage form, US Patent Application (2002) 20020015731.
W.J. Curatolo, K.C. Waterman, A.G. Thombre, M.B. Fergione, M.C. Roy, L.E. Appel, D. Supplee, D.T. Friesen, M.B. Chidlaw, R.A. Beyerinck, ‘‘Hydrogel-driven layered drug dosage form’’, US Patent Application, (2001) 20010044474.
B. Eckenhoff, F. Theeuwes, J. Urquhart, Osmotically actuated dosage forms for rate-controlled drug delivery, Pharmaceutical Technology.1981;5(1):35– 44.
Higuchi T, Leeper HM. Improved osmotic dispenser employing magnesium sulfate and magnesium chloride. US Patent 3760804, 1973.
Harkrishan Sinsh & Kapoor. V.K. Medicinal and pharmaceutical chemistry.2005 ;( 2); reprint- 2007:377.
K.D tripathi: Essentials of Medical pharmacology 5th edition:235-45.
http// www.expresspharmaonline.com /20030821/research01.html
http//www.expresspharmaonline.com/20030828/ research01.html
www.invega.com
Reza MS, Quadir MA and Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery’ Pharm Sci. 2003; 6(2):282-91.
Dwarakanadha Reddy P and Swarnalatha D. Recent Advances in Novel Drug Delivery systems. Int J Pharm Tech Res. 2010;2(3):2025–2027.
Zenter GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Contr.Rel.1985;(1):269-82.
Rani M, Surana R, Sankar C, Mishra B. Development and biopharmaceutical evaluation of osmotic pump tablets for controlled delivery of diclofenac sodium. Acta Pharm 2003;53:263-73.
Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine I. Cellulose acetate as a semipermeable membrane. J Contr. Rel 2003;89:5-18.
Kanagale P, Lohray BB, Misra A, Davadra P, Kini R. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. AAPS Pharm Sci Tech 2007; 8(3):1-7.
Lu EX, Jiang ZQ, Zhang QZ, Jiang XQ. A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent. J Control Rel 2003;92:375-82.
Gondaliya D, Pundarikakshudu K. The fabrication and evaluation of the formulation variables of a controlled porosity osmotic drug delivery system with diltiazem hydrochloride. Pharma Techno 2003:58-68.
Vyas SP, Guleria R, Singh R. Development and in- vitro characterization of elementary osmotic pump bearing ciprofloxacin HCl. The Eastern Pharmacist 1995;38(447):133-5.
Hui L, Xing-Gang Y, Shu-Fang N, Lan-Lan W, Li-Li Z, Hong L et al. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation. Int J of Pharm. 2007; 332(1-2):115-24.
Zenter GM, McClelland GA, Sutton SC. Controlled porosity solubilityand resin- modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Contr. Rel 1991; 16:237-44.
Okimoto K, Rajewski RA, Stella VJ. Release of testosterone from an osmotic pump tablet utilizing (SBE) 7m-β-cyclodextrin as both a solubilizing and an osmotic pump agent. J Contr. Rel 1999; 58:29-38.
Kazuto O, Atsuo O, Rinta I, Osamu A, Norio O, Tetsumi I et al. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7M-β-CD. Pharm Res 1999;16(4):549-54.
Prabakaran D, Singh P, Kanauja P, Vyas SP. Effect of hydrophilic polymers on the release of diltiazem hydrochloride from elementary osmotic pumps. Int J Pharm 2003;259:173-9.
Mishra B, Srivastava S, Singh S, Sankar C. Oral osmotic pumps for poorly water soluble drug-rofecoxib: formulation development perspective. Ind Drugs 2006;43(7):553-61.
Longxiao L, Jinchao W, Suyan Z. Delivery of prazosin hydrochloride from osmotic pump system prepared by coating the core tablet with an indentation. Drug Delivery 2007;14:219-24.
Sutthilug S, John LH, Valentino JS. Controlled porosity-osmotic pump pellets of a poorly water-soluble drug using sulfobutyl ether-β-cyclodextrin, (SBE)7M-β-CD, as a solubilizing and osmotic agent. J of Pharm Sci 2007;96(9):2364-74.
Verma RK, Kaushal AM, Garg S. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. Int J Pharm 2003;263:9-24.
Kumar P, Singh S, Mishra B. Drug delivery system of ranitidine hydrochloride based on osmotic technology: development and evaluation. Current Drug Delivery 2008;5:332-42.
Prabakaran D, Singh P, Kanaujia P, Jaganathan KS, Rawat A, Vyas SP. Modified push-pull osmotic system for simultaneous delivery of theophylline and salbutamol: development and in vitro characterization. Int J Pharm 2004;284:95-108.
Longxioa L, Xiangning X. Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int J Pharm 2008;352:225-30.
Shokri J, Ahmadi P, Rashidi P, Shahsavari M, Ali R, Ali N. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm 2008; 68:289-97.
Longxioa L, Xiaociu W. Solubility-modulated monolithic osmotic pump tablet for atenolol delivery. Eur J Pharm Biopharm 2008;68:298-302.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Sheskey P.J. Handbook of Pharmaceutical Excipients, 4th edition, Royal Pharmaceutical Society of Great Britain, London, 2003:213.
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th edition The Pharmaceutical Press; London: 2006; 346-49.
Salomon, J.L., Doelker, Buri, Pharma. Acta Helv; 1979:54-82.
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th edition The Pharmaceutical Press; London: 2006; 111-16.
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th edition The Pharmaceutical Press; London: 2006;821-823.
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th edition The Pharmaceutical Press; London: 2006;821-823.
Sheskey P.J. Handbook of Pharmaceutical Excipients, 4th edition, Royal Pharmaceutical Society of Great Britain, London, 2003; 89.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Sheskey P.J. Handbook of Pharmaceutical Excipients, 4th edition, Royal Pharmaceutical Society of Great Britain, London, 2003:186.
Rowe RC, Sheskey PJ, Weller PJ. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2003.
Kibbe AH. Handbook of pharmaceutical excipients. 3rd ed. Washington: American Pharmaceutical Association; 2000.
Indian Pharmacopoeia. The Controller of Publications, Ministry of health and welfare, New Delhi: 1996.
C.V.S. Subramanyam, Text book of Physical Pharmaceutics, thoroughly revised and enlarge,:202.
IP, Indian pharmacopoeia 1996, vol-II, Appendix 8.15, A-99.
C.V.S. Subramanyam, Text book of Physical Pharmaceutics, thoroughly revised and enlarge:258.
Martin, Physical Pharmacy, 4th edition, p-332.
Lechman, L., Liberman, H.A., Kanig, J.L., In., The Theory and Practice of Industrial Pharmacy, 3rd Ed., Varghese Publishing House, Bombay, 1987:297.
Lechman, L., Liberman, H.A., Kanig, J.L., In., The Theory and Practice of Industrial Pharmacy, 3rd Ed., Varghese Publishing House, Bombay, 1987:249.
IP, Indian pharmacopoeia 1996; vol-II, Appendix 7.3, A-82.
Phanidhar Sastri, , Ravikumar, Atin Kalra, Mahalaxmi.R Pritam Kanagale.D2 , Narkhede R. “Enhancement of Dissolution of Glipizide from Controlled Porosity Osmotic Pump Using A Wicking Agent And A Solubilizing Agent” International Journal of PharmTech Research Vol.1, No.3;July-Sept 2009:705-711.
Verma RK, Kaushal AM, Garg S. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology Int J Pharm 2003;263:9-24.
Korsemeyer RW, PeppasNA. Macromolecular and modeling aspects of swelling – controlled Systems. In: Mansdrofsz, Roseman TJ, ad, Controlled Release Delivery systems. New – York, NY: Marcel Dekker; 1983:77.
Kumar V. "Designing of stability programme", The Eastern Pharmacist, 1992, 35(416), 29.
Lieberman HA, Lachman L, Schwartz JB. Pharmaceutical Dosage Forms: Tablet, Vol 1. New York; Marcel Dekker; 2005.